Media headlines about Globus Medical (NYSE:GMED) have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Globus Medical earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 46.4174427574417 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Globus Medical, Inc. (GMED) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Globus Medical Announces First Spine Surgeries Using ExcelsiusGPS™ (finance.yahoo.com)
- Globus Medical, Inc. (GMED) Upgraded at BidaskClub (americanbankingnews.com)
- Globus Medical, Inc. (GMED) Upgraded to Hold at Zacks Investment Research (americanbankingnews.com)
- Globus Medical, Inc. – Value Analysis (NYSE:GMED) : October 4, 2017 (finance.yahoo.com)
Globus Medical (GMED) opened at 29.69 on Wednesday. The firm has a 50-day moving average of $29.93 and a 200-day moving average of $30.90. The company has a market capitalization of $2.86 billion, a P/E ratio of 26.75 and a beta of 0.56. Globus Medical has a one year low of $19.25 and a one year high of $34.03.
Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.02. The business had revenue of $152.39 million during the quarter, compared to analysts’ expectations of $150.94 million. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 EPS. On average, analysts anticipate that Globus Medical will post $1.26 earnings per share for the current year.
GMED has been the subject of a number of research reports. BidaskClub lowered shares of Globus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 26th. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research note on Monday, September 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Globus Medical in a research note on Friday, August 18th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Globus Medical in a research note on Wednesday, August 30th. Finally, BTIG Research initiated coverage on shares of Globus Medical in a research note on Thursday, September 7th. They issued a “buy” rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $30.71.
WARNING: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/10/11/globus-medical-gmed-given-news-impact-rating-of-0-19.html.
In related news, insider A Brett Murphy sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $29.99, for a total transaction of $449,850.00. Following the completion of the sale, the insider now owns 101,217 shares in the company, valued at $3,035,497.83. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 28.21% of the company’s stock.
Globus Medical Company Profile
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.